Fine Foods & Pharmaceuticals Ntm
ISIN: IT0005215329 | Ticker: FF | LEI: 8156009111DEE8553765
Country: Italy
Fine Foods is active in the contract manufacturing and development of oral solid forms for the pharmaceutical and nutraceutical industries and in the cosmetics, medical aid and biocide sectors through its Euro Cosmetic and Pharmatek-PMC production facilities.
Year founded1984
Served areaWorldwide
Headcount750
HeadquartersVia Berlino 39, 24040 Zingonia-Verdellino – Italy
| Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 302,810,211.00 | 299,820,309.00 |
| Noncurrent Assets | N/A | 131,259,960.00 | 135,147,200.00 |
| Property Plant And Equipment | N/A | 102,886,510.00 | 104,162,050.00 |
| Goodwill | N/A | 15,907,954.00 | 15,907,954.00 |
| Intangible Assets Other Than Goodwill | N/A | 2,337,675.00 | 1,780,551.00 |
| Deferred Tax Assets | N/A | 3,482,100.00 | 7,312,662.00 |
| Other Noncurrent Nonfinancial Assets | N/A | 237,333.00 | 820,871.00 |
| Current Assets | N/A | 171,550,251.00 | 164,673,109.00 |
| Inventories | N/A | 35,050,484.00 | 40,422,499.00 |
| Current Trade Receivables | N/A | 29,433,391.00 | 39,347,321.00 |
| Current Tax Assets Current | N/A | 2,421,853.00 | 2,268,044.00 |
| Cash and cash equivalents | 3,342,518.00 | 17,118,957.00 | 10,232,262.00 |
| Other Current Assets | N/A | 9,554,455.00 | 5,890,398.00 |
| Equity And Liabilities | N/A | 302,810,211.00 | 299,820,309.00 |
| Equity | 141,008,161.00 | 147,217,991.00 | 133,289,763.00 |
| Issued Capital | N/A | 22,770,445.00 | 22,770,445.00 |
| Retained Earnings | N/A | 0.00 | 22,610.00 |
| Other Reserves | N/A | 132,615,098.00 | 126,461,456.00 |
| Noncurrent Liabilities | N/A | 45,885,684.00 | 82,496,684.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 3,010,691.00 | 2,419,013.00 |
| Other Longterm Provisions | N/A | 35,489.00 | 41,105.00 |
| Deferred Tax Liabilities | N/A | 1,081,159.00 | 240,553.00 |
| Longterm Borrowings | N/A | 35,298,177.00 | 77,573,797.00 |
| Noncurrent Portion Of Noncurrent Bonds Issued | N/A | 3,322,876.00 | 0.00 |
| Current Liabilities | N/A | 109,706,537.00 | 84,033,862.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 32,532,117.00 | 33,450,468.00 |
| Current Tax Liabilities Current | N/A | 5,536.00 | 0.00 |
| Other Current Financial Liabilities | N/A | 8,096,854.00 | 10,018,421.00 |
| Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued | N/A | 3,310,176.00 | 3,323,051.00 |
| Line item in (eur) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 195,244,559.00 | 208,319,727.00 |
| Revenue From Contracts With Customers | 194,849,556.00 | 206,852,576.00 |
| Services Expense | 20,839,099.00 | 25,190,520.00 |
| Employee Benefits Expense | 34,823,128.00 | 38,300,569.00 |
| Depreciation And Amortisation Expense | 14,527,508.00 | 16,420,419.00 |
| Profit Loss From Operating Activities | 5,034,230.00 | -1,011,413.00 |
| Finance Income | 36,202.00 | 59,214.00 |
| Finance Costs | 763,305.00 | 2,246,228.00 |
| Profit Loss Before Tax | -4,590,253.00 | -14,198,912.00 |
| Income Tax Expense Continuing Operations | -3,163,501.00 | -4,697,768.00 |
| Profit (loss) | -1,426,751.00 | -9,501,145.00 |
| Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | -1,426,751.00 | -9,501,145.00 |
| Adjustments For Income Tax Expense | N/A | -1,301,460.00 | 68,715.00 |
| Adjustments For Finance Costs | N/A | 745,520.00 | 2,179,317.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -9,992,403.00 | -5,944,094.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 1,995,703.00 | 918,351.00 |
| Adjustments For Provisions | N/A | 0.00 | 39,000.00 |
| Other Adjustments For Noncash Items | N/A | 1,058,445.00 | 0.00 |
| Interest Paid Classified As Operating Activities | N/A | -712,535.00 | -2,156,964.00 |
| Cash Flows From Used In Operating Activities | N/A | -5,826,715.00 | 3,688,374.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 18,353,280.00 | 0.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 239,717.00 | 209,017.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 14,849,438.00 | 15,026,843.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 1,070,725.00 | 957,395.00 |
| Cash Flows From Used In Investing Activities | N/A | -36,347,779.00 | -15,314,586.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 90,066,513.00 | 72,744,341.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 12,313,170.00 | 62,175,238.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 520,326.00 | 1,091,921.00 |
| Dividends Paid Classified As Financing Activities | N/A | 3,205,727.00 | 3,866,869.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | -11,064,496.00 | 0.00 |
| Cash Flows From Used In Financing Activities | N/A | 55,950,934.00 | 4,739,517.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 13,776,440.00 | -6,886,695.00 |
| Cash and cash equivalents | 3,342,518.00 | 17,118,957.00 | 10,232,262.00 |
Please note that some sums might not add up.
IT0005215329
LEI8156009111DEE8553765
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.